https://m2.mtmt.hu/ hun 2026-09-20 23:06 JournalArticle 36250637 APPROVED true Semmelweis Egyetem, Center for Pharmacology and Drug Research & Development, Budapest, Hungary Semmelweis Egyetem, Budapest, Hungary Export Date: 06 November 2025; Cited By: 1; Correspondence Address: R. Zelkó; Center of Pharmacology and Drug Research & Development, Semmelweis University, Budapest, 1085, Hungary; email: zelko.romana@semmelweis.hu; B. Hankó; Center of Pharmacology and Drug Research & Development, Semmelweis University, Budapest, 1085, Hungary; email: balazs.hanko@kim.gov.hu 0 false 2026-09-16T12:36:32.164+0000 2026-07-21T08:29:46.188+0000 2025-07-16T06:47:05.091+0000 true 10015206 Áncsán Gizella /api/admin/10015206 Admin Áncsán Gizella (SE admin) true 10015206 2026-07-21T08:29:46.471+0000 2026-07-21T08:29:46.471+0000 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Artner, Anna true true /api/journal/10071822 REVIEWED GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) 2509-2715 2509-2723 true false 10071822 false 10071822 true 2509-2715 2509-2723 Journal FOREIGN 48 3 4745 4767 4745 23 2026 Statins are crucial in lipid-lowering therapy for reducing atherosclerotic cardiovascular disease (ASCVD) risk. However, rhabdomyolysis, a rare but severe side effect, disproportionately affects frail, older adults with polypharmacy and multiple comorbidities. Current guidelines for adjusting statin dosages in older adults lack clarity. To evaluate statin use in the geriatric population, assess benefit-risk ratios, and analyze dosage regimens through a systematic literature review. A comprehensive search was conducted in PubMed, Scopus, Web of Science, and EBSCO databases. Eleven original studies involving 566,509 patients were included. The review was registered on PROSPERO (CRD42024587259). Statin therapy was associated with a lower risk of cardiovascular disease compared to placebo. When adjusted during treatment, higher-intensity statins appeared to provide greater benefits than fixed low-dose statins, while the likelihood of side effects remained similar. Using ezetimibe and statins further improved outcomes and was linked to fewer side effects. Adherence-improving techniques were crucial, especially in older adults. Individualized statin dosing, considering titration, combination therapy, and adherence strategies, is essential for maximizing benefits and minimizing risks in older adults. While statins effectively reduce CVD risk, careful consideration of patient-specific factors is necessary when prescribing to older adults. Funding 2055544 /api/funding/2055544 (Open access funding provided by Semmelweis University) false true true 2025 true true true false true false NONE 2026-09-16 false 4 0 4 3 1 4 4 3 3 3 3 2 2 3 1 0 4 3 4 3 0 1 1 Folyóiratcikk Journal Article 24 4 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2025 0 1 1 1 1 2026 0 3 2 3 2 D1 false false false false 2025-10-14T06:47:12.318+0000 Egyetemi Gyógyszertár Gyógyszerügyi Szervezési ... (SE / GYTK); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 3 8 2 3 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 127286986 /api/authorship/127286986 Artner, Anna [Artner, Anna (gyógyszerészi gon...), szerző] Egyetemi Gyógyszertár Gyógyszerügyi Szervezési ... (SE / GYTK); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 1 0.333 true false false Author 10090122 /api/author/10090122 Artner Anna (gyógyszerészi gondozás) Artner Anna true true Artner Anna true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 127286987 /api/authorship/127286987 Zelkó, Romána ✉ [Zelkó, Romána (Gyógyszertechnológia), szerző] Egyetemi Gyógyszertár Gyógyszerügyi Szervezési ... (SE / GYTK); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 2 0.333 false false true Author 10002587 /api/author/10002587 Zelkó Romána (Gyógyszertechnológia) Zelkó Romána true 10002587 true Zelkó Romána true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 127286988 /api/authorship/127286988 Hankó, Balázs ✉ [Hankó, Balázs (gyógyszerügyi sze...), szerző] Egyetemi Gyógyszertár Gyógyszerügyi Szervezési ... (SE / GYTK); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 3 0.333 false true true Author 10020592 /api/author/10020592 Hankó Balázs (gyógyszerügyi szervezéstan) Hankó Balázs true 10020592 true Hankó Balázs true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 29606417 /api/publicationidentifier/29606417 DOI: 10.1007/s11357-025-01772-w PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.1007/s11357-025-01772-w https://doi.org/10.1007/s11357-025-01772-w false true PublicationIdentifier 29629565 /api/publicationidentifier/29629565 WoS: 001529112200001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001529112200001 https://www.webofscience.com/wos/woscc/full-record/001529112200001 true true PublicationIdentifier 29837641 /api/publicationidentifier/29837641 Scopus: 105010729940 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 105010729940 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105010729940 false true PublicationIdentifier 29646290 /api/publicationidentifier/29646290 PubMed: 40665098 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true 40665098 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40665098&dopt=Abstract true true SjrRating 11734232 /api/sjrrating/11734232 sjr:D1 (2026) Scopus - Veterinary (miscellaneous) GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) 2509-2715 2509-2723 2 0.0 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 3401 /api/classificationexternal/3401 Scopus - Veterinary (miscellaneous) true 3401 true D1 FROM_LAST_YEAR true true Reference 66905954 /api/reference/66905954 1. Rochat M, et al. Ten-year evolution of statin eligibility and use in a population-based cohort. Am J Cardiol. 2023;187:138–47., DOI: 10.1016/j.amjcard.2022.10.013 1 10.1016/j.amjcard.2022.10.013 false true Reference 66905955 /api/reference/66905955 2. Horodinschi RN, et al. Treatment with statins in elderly patients. Med (Kaunas). 2019; 55(11)., DOI: 10.3390/medicina55110721 2 10.3390/medicina55110721 false true Reference 66905956 /api/reference/66905956 3. Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88., DOI: 10.1093/eurheartj/ehz455 3 10.1093/eurheartj/ehz455 false true Reference 66905957 /api/reference/66905957 4. Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1046–81. 4 false true Reference 66905958 /api/reference/66905958 5. Lipka L, et al. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging. 2004;21(15):1025–32., DOI: 10.2165/00002512-200421150-00005 5 10.2165/00002512-200421150-00005 false true Reference 66905959 /api/reference/66905959 6. Neil HAW, et al. Analysis of efficacy and safety in patients aged 65–75 years at randomization. Diabetes Care. 2006;29(11):2378–84., DOI: 10.2337/dc06-0872 6 10.2337/dc06-0872 false true Reference 66905960 /api/reference/66905960 7. Koren MJ, Feldman T, Mendes RA. Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years. Clin Cardiol. 2009;32(5):256–63., DOI: 10.1002/clc.20448 7 10.1002/clc.20448 false true Reference 66905961 /api/reference/66905961 8. Zieve F, et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Am J Cardiol. 2010;105(5):656–63., DOI: 10.1016/j.amjcard.2009.10.029 8 10.1016/j.amjcard.2009.10.029 false true Reference 66905962 /api/reference/66905962 9. Bays HE, et al. Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease. Int J Cardiol. 2011;153(2):p.141–7., DOI: 10.1016/j.ijcard.2010.08.043 9 10.1016/j.ijcard.2010.08.043 false true Reference 66905963 /api/reference/66905963 10. Stender S, Budinski D, Hounslow N. Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol. 2013;20(1):29–39., DOI: 10.1177/2047487312437326 10 10.1177/2047487312437326 false true Reference 66905964 /api/reference/66905964 11. Constance C, et al. Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years. Lipids in Health and Disease. 2014;13., DOI: 10.1186/1476-511X-13-13 11 10.1186/1476-511X-13-13 false true Reference 66905965 /api/reference/66905965 12. Campitelli MA, et al. One-year survival and admission to hospital for cardiovascular events among older residents of long-term care facilities who were prescribed intensive- and moderate-dose statins. Canadian Medical Association Journal (CMAJ). 2019;191(2):E32–9., DOI: 10.1503/cmaj.180853 12 10.1503/cmaj.180853 false true Reference 66905966 /api/reference/66905966 13. Musich S, et al. Underutilization of statin therapy for secondary prevention of cardiovascular disease among older adults. Popul Health Manag. 2019;22(1):74–82., DOI: 10.1089/pop.2018.0051 13 10.1089/pop.2018.0051 false true Reference 66905967 /api/reference/66905967 14. Mack DS, et al. Prevalent statin use in long-stay nursing home residents with life-limiting illness. J Am Geriatr Soc. 2020;68(4):708–16., DOI: 10.1111/jgs.16336 14 10.1111/jgs.16336 false true Reference 66905968 /api/reference/66905968 15. Spencer-Bonilla G, et al. Statin use in older adults with stable atherosclerotic cardiovascular disease. J Am Geriatr Soc. 2021;69(4):979–85., DOI: 10.1111/jgs.16975 15 10.1111/jgs.16975 false true Reference 66905969 /api/reference/66905969 16. Page MJ, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160. 16 false true Reference 66905970 /api/reference/66905970 17. Atkins D, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004;4(1):38., DOI: 10.1186/1472-6963-4-38 17 10.1186/1472-6963-4-38 false true Reference 66905971 /api/reference/66905971 18. Health, N.I.o. Quality assessment tool for observational cohort and cross-sectional studies. 2022 [cited 2024 2024.09.18]; Available from: https://pubmed.ncbi.nlm.nih.gov/15615589/. 18 false true Reference 66905972 /api/reference/66905972 19. Pasternak RC, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40(3):567–72., DOI: 10.1016/S0735-1097(02)02030-2 19 10.1016/S0735-1097(02)02030-2 false true Reference 66905973 /api/reference/66905973 20. Grover SA, et al. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Arch Intern Med. 2009;169(19):1775–80., DOI: 10.1001/archinternmed.2009.328 20 10.1001/archinternmed.2009.328 false true Reference 66905974 /api/reference/66905974 21. Yourman LC, et al. Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis. JAMA Intern Med. 2021;181(2):179–85., DOI: 10.1001/jamainternmed.2020.6084 21 10.1001/jamainternmed.2020.6084 false true Reference 66905975 /api/reference/66905975 22. Ford I, et al. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study. Circulation. 2016;133(11):1073–80., DOI: 10.1161/CIRCULATIONAHA.115.019014 22 10.1161/CIRCULATIONAHA.115.019014 false true Reference 66905976 /api/reference/66905976 23. Gunta SP, et al. PCSK9 inhibitor, ezetimibe, and bempedoic acid: evidence-based therapies for statin-intolerant patients. Prog Cardiovasc Dis. 2023;79:12–8., DOI: 10.1016/j.pcad.2023.02.007 23 10.1016/j.pcad.2023.02.007 false true Reference 66905977 /api/reference/66905977 24. EMA Eudravigilance, European Medicines Agency. (2024). https://www.adrreports.eu/hu/search_subst.html 24 false true Reference 66905978 /api/reference/66905978 25. Strandberg TE, Kolehmainen L, Vuorio A. Evaluation and treatment of older patients with hypercholesterolemia: a clinical review. JAMA. 2014;312(11):1136–44., DOI: 10.1001/jama.2014.10924 25 10.1001/jama.2014.10924 false true Reference 66905979 /api/reference/66905979 26. Davis HR Jr, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem. 2004;279(32):33586–92., DOI: 10.1074/jbc.M405817200 26 10.1074/jbc.M405817200 false true Reference 66905980 /api/reference/66905980 27. Cohen DE. Balancing cholesterol synthesis and absorption in the gastrointestinal tract. J Clin Lipidol. 2008;2(2):S1-3., DOI: 10.1016/j.jacl.2008.01.004 27 10.1016/j.jacl.2008.01.004 false true Reference 66905981 /api/reference/66905981 28. Cannon CP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97., DOI: 10.1056/NEJMoa1410489 28 10.1056/NEJMoa1410489 false true Reference 66905982 /api/reference/66905982 29. Betters JL, Yu L. NPC1L1 and cholesterol transport. FEBS Lett. 2010;584(13):2740–7., DOI: 10.1016/j.febslet.2010.03.030 29 10.1016/j.febslet.2010.03.030 false true Reference 66905983 /api/reference/66905983 30. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415–27. 30 false true Reference 66905984 /api/reference/66905984 31. van Heek M, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol. 2000;129(8):1748–54., DOI: 10.1038/sj.bjp.0703235 31 10.1038/sj.bjp.0703235 false true Reference 66905985 /api/reference/66905985 32. Awad K, et al. Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. BMC Med. 2021;19(1):139., DOI: 10.1186/s12916-021-02009-1 32 10.1186/s12916-021-02009-1 false true Reference 66905986 /api/reference/66905986 33. Turin A, Pandit J, Stone NJ. Statins and nonadherence: should we RELATE better? J Cardiovasc Pharmacol Ther. 2015;20(5):447–56., DOI: 10.1177/1074248415578170 33 10.1177/1074248415578170 false true Reference 66905987 /api/reference/66905987 34. Rosenson RS, et al. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. J Am Coll Cardiol. 2015;65(3):270–7., DOI: 10.1016/j.jacc.2014.09.088 34 10.1016/j.jacc.2014.09.088 false true Reference 66905988 /api/reference/66905988 35. Kolandaivelu K, et al. Non-adherence to cardiovascular medications. Eur Heart J. 2014;35(46):3267–76., DOI: 10.1093/eurheartj/ehu364 35 10.1093/eurheartj/ehu364 false true Reference 66905989 /api/reference/66905989 36. Marcum ZA, et al. Pharmacist-led interventions to improve medication adherence in older adults: a meta-analysis. J Am Geriatr Soc. 2021;69(11):3301–11., DOI: 10.1111/jgs.17373 36 10.1111/jgs.17373 false true Reference 66905990 /api/reference/66905990 37. Taibanguay N, et al. Effect of patient education on medication adherence of patients with rheumatoid arthritis: a randomized controlled trial. Patient Prefer Adherence. 2019;13:119–29., DOI: 10.2147/PPA.S192008 37 10.2147/PPA.S192008 false true Reference 66905991 /api/reference/66905991 38. Jörntén-Karlsson M, et al. Patient-centered interventions to improve adherence to statins: a narrative synthesis of systematically identified studies. Drugs. 2016;76(15):1447–65., DOI: 10.1007/s40265-016-0640-x 38 10.1007/s40265-016-0640-x false true Reference 66905992 /api/reference/66905992 39. Mackridge AJ, Wood EM, Hughes DA. Improving medication adherence in the community: a purposive umbrella review of effective patient-directed interventions that are readily implementable in the United Kingdom National Health Service. Int J Clin Pharm. 2025;47(3):640–53. https://doi.org/10.1007/s11096-025-01885-4., DOI: 10.1007/s11096-025-01885-4 39 10.1007/s11096-025-01885-4 false true Reference 66905993 /api/reference/66905993 40. Wei Q, et al. Medication adherence with fixed-dose versus free-equivalent combination therapies: systematic review and meta-analysis. Front Pharmacol. 2023;14:1156081., DOI: 10.3389/fphar.2023.1156081 40 10.3389/fphar.2023.1156081 false true Reference 66905994 /api/reference/66905994 41. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008;23(5):611–4., DOI: 10.1007/s11606-008-0544-x 41 10.1007/s11606-008-0544-x false true Reference 66905995 /api/reference/66905995 42. German CA, Liao JK. Understanding the molecular mechanisms of statin pleiotropic effects. Arch Toxicol. 2023;97(6):1529–45., DOI: 10.1007/s00204-023-03492-6 42 10.1007/s00204-023-03492-6 false true Reference 66905996 /api/reference/66905996 43. Nanna MG, et al. Primary prevention statin therapy in older adults. Curr Opin Cardiol. 2023;38(1):11–20., DOI: 10.1097/HCO.0000000000001003 43 10.1097/HCO.0000000000001003 false true Reference 66905997 /api/reference/66905997 44. Mangione CM, et al. Statin use for the primary prevention of cardiovascular disease in adults US Preventive Services Task Force recommendation statement. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2022;328(8):746–53., DOI: 10.1001/jama.2022.13044 44 10.1001/jama.2022.13044 false true Reference 66905998 /api/reference/66905998 45. Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?” Lancet. 2005;365(9453):82–93., DOI: 10.1016/S0140-6736(04)17670-8 45 10.1016/S0140-6736(04)17670-8 false true Reference 66905999 /api/reference/66905999 46. Wallerstein, N. and B. Duran, Community-based participatory research contributions to intervention research: the intersection of science and practice to improve health equity. Am J Public Health, 2010. 100 Suppl 1(Suppl 1): p. S40–6., DOI: 10.2105/AJPH.2009.184036 46 10.2105/AJPH.2009.184036 false true Reference 66906000 /api/reference/66906000 47. Veronese N, et al. Comprehensive geriatric assessment in older people: an umbrella review of health outcomes. Age Ageing. 2022;51(5). 47 false true /api/publication/36250637 Artner Anna et al. Optimizing Statin Therapy in Older Adults: A Systematic Review of Dosing, Titration, and Combination Strategies. (2026) GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) 2509-2715 2509-2723 48 3 4745-4767<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10090122"><a href="/gui2/?type=authors&mode=browse&sel=10090122" target="_blank">Artner Anna (<span class="authorship-author-name">Artner Anna</span> <span class="authorAux-mtmt"> gyógyszerészi gondozás</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Egyetemi Gyógyszertár Gyógyszerügyi Szervezési Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10002587"><a href="/gui2/?type=authors&mode=browse&sel=10002587" target="_blank">Zelkó Romána ✉ (<span class="authorship-author-name">Zelkó Romána</span> <span class="authorAux-mtmt"> Gyógyszertechnológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Egyetemi Gyógyszertár Gyógyszerügyi Szervezési Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10020592"><a href="/gui2/?type=authors&mode=browse&sel=10020592" target="_blank">Hankó Balázs ✉ (<span class="authorship-author-name">Hankó Balázs</span> <span class="authorAux-mtmt"> gyógyszerügyi szervezéstan</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Egyetemi Gyógyszertár Gyógyszerügyi Szervezési Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;36250637" target="_blank">Optimizing Statin Therapy in Older Adults: A Systematic Review of Dosing, Titration, and Combination Strategies</a></div> <div> <span class="journal-title">GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE)</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/2509-2715">2509-2715</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/2509-2723">2509-2723</a>)</span>: <span class="journal-volume">48</span> <span class="journal-issue">3</span> <span class="page"> pp 4745-4767 </span> <span class="year">(2026)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.1007/s11357-025-01772-w" target="_blank" href="https://doi.org/10.1007/s11357-025-01772-w"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001529112200001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001529112200001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="105010729940" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105010729940"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:black" title="40665098" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40665098&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Complementary and Alternative Medicine&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Geriatrics and Gerontology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Veterinary (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Aging&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Cardiology and Cardiovascular Medicine&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 4</span> | Független: 3 | Függő: 1 | Nem jelölt: 0 | WoS jelölt: 3 | Scopus jelölt:&nbsp;3 | WoS/Scopus jelölt:&nbsp;3 | DOI jelölt:&nbsp;4 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;36250637&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 1 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 36250637</span> | <span class="status-data status-APPROVED"> Nyilvános </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Összefoglaló cikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">Scopus</span> </div> <div class="funder"> (Open access funding provided by Semmelweis University) </div> <div class="lastModified">Utolsó módosítás: 2026.07.21. 10:29 Molnár-Taga Márta (SE 4-es admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Semmelweis Egyetem, Center for Pharmacology and Drug Research & Development, Budapest, Hungary Semmelweis Egyetem, Budapest, Hungary Export Date: 06 November 2025; Cited By: 1; Correspondence Address: R. Zelkó; Center of Pharmacology and Drug Research & Development, Semmelweis University, Budapest, 1085, Hungary; email: zelko.romana@semmelweis.hu;...</pre> </div></div>